Drugs / Omega-3 fatty acid administration
Omega-3 fatty acid administration
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00346697 | Oct 2006 → Apr 2010 | AIDS, hyperlipidemia, hypertriglyceridemia | Brown, Todd, M.D., Ph.D. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-11-14 | GlaxoSmithKline | Results New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients gsk.com ↗
The study showed no benefit in reducing the recurrence of symptomatic AF in patient groups treated with high-dose, prescription omega-3 fatty acids and placebo. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-09-13 | GlaxoSmithKline | GSK statement in response to patent ruling reversal on Lovaza gsk.com ↗ |
| 2012-05-29 | GlaxoSmithKline | GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents gsk.com ↗ |
| 2011-03-30 | GlaxoSmithKline | GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ US patent litigation gsk.com ↗ |
| 2010-11-14 | GlaxoSmithKline | New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega-3 fatty acid administration | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00346697 ↗ |
| Known as | LOVAZA | “It is 8- week randomized, double-blind trial of omega-3 fatty acids (LOVAZA, GSK, Inc) compared to placebo in 48 HAART-treated HIV-infected patients with triglycerides between...” NCT00346697 ↗ |
| Known as | O3A | “We performed a randomized placebo-controlled trial of omega-3-acid (O3A) ethyl esters in HIV-infected patients with hypertriglyceridaemia, hypothesizing that O3A would decrease...” PMID 23683266 ↗ May 2013 |